Catabasis Pharmaceuticals (NASDAQ:CATB) had its target price cut by Citigroup from $2.50 to $1.50 in a report released on Friday, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other brokerages also recently commented on CATB. Zacks Investment Research downgraded shares of Catabasis Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, May 11th. ValuEngine raised shares of Catabasis Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, May 2nd. Finally, Wedbush set a $3.00 target price on shares of Catabasis Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 9th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $4.54.

Shares of CATB opened at $0.65 on Friday. Catabasis Pharmaceuticals has a 52 week low of $0.61 and a 52 week high of $3.78. The company has a market cap of $19.51 million, a P/E ratio of -0.52 and a beta of 0.56.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.03. equities analysts anticipate that Catabasis Pharmaceuticals will post -1.04 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Federated Investors Inc. PA bought a new stake in Catabasis Pharmaceuticals in the second quarter worth approximately $10,006,000. Renaissance Technologies LLC grew its position in Catabasis Pharmaceuticals by 167.2% in the fourth quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock worth $698,000 after acquiring an additional 293,300 shares in the last quarter. Deutsche Bank AG bought a new stake in Catabasis Pharmaceuticals in the fourth quarter worth approximately $335,000. Finally, Geode Capital Management LLC grew its position in Catabasis Pharmaceuticals by 146.1% in the fourth quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 45,476 shares in the last quarter. 26.83% of the stock is owned by institutional investors.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.

See Also: Diversification in Your Portfolio

The Fly

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.